BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25304315)

  • 1. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
    Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M
    Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
    Jiang L; Zhang W; Li W; Ling C; Jiang M
    Toxicol Lett; 2018 Jan; 282():154-165. PubMed ID: 29050931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.
    Arora R; Yates C; Gary BD; McClellan S; Tan M; Xi Y; Reed E; Piazza GA; Owen LB; Dean-Colomb W
    PLoS One; 2014; 9(6):e98370. PubMed ID: 24896091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNAs as targets for immunosuppressive drug teriflunomide in anti-cancer potential for hepatocellular carcinoma.
    Xu Y; Shen D; Liu J; Xu X; Tu J; Qin L; Jiang L; Qian H; Guo F
    J Mol Histol; 2020 Dec; 51(6):659-673. PubMed ID: 33034797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
    Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
    Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
    Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
    BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
    Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
    Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
    Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
    PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
    Bilir B; Kucuk O; Moreno CS
    J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
    Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
    Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
    Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
    Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.